RecruitingNCT07803874

UV-Trichoscopic Red Fluorescence in Alopecia Areata

Evaluation of UV-Trichoscopic Red Fluorescence Intensity in Relation to Trichoscopic Findings and Response to Intralesional Corticosteroid Treatment in Limited Plaque-Type Alopecia Areata


Sponsor

Istanbul Training and Research Hospital

Enrollment

40 participants

Start Date

Jul 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to learn whether red fluorescence seen with ultraviolet (UV) trichoscopy is related to disease findings and treatment response in adults with limited plaque-type alopecia areata. Trichoscopy is a close-up imaging method used to examine the hair and scalp. The study will investigate whether the amount of red fluorescence at the beginning of the study is related to how soon hair starts to grow back, how much hair regrows, and how trichoscopic findings change during follow-up. Participants for whom intralesional corticosteroid treatment has been planned as part of their regular medical care will have standard trichoscopic and UV-trichoscopic images taken of the affected scalp area. They will be followed at weeks 4, 8, and 12, when hair regrowth and changes in scalp and hair findings will be evaluated. Researchers will measure red fluorescence in the images and examine whether it is related to treatment response over time.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Triamcinolone Acetonide for people with alopecia areata. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTriamcinolone Acetonide

Intralesional triamcinolone acetonide is administered for limited plaque-type alopecia areata as part of routine clinical care. The decision to administer treatment is made independently of participation in this observational study. The study prospectively evaluates trichoscopic and UV-trichoscopic findings and hair regrowth during routine treatment follow-up.


Locations(1)

Istanbul Training and Research Hospital

Istanbul, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07803874


Related Trials